AMP-Activated Protein Kinase and Host Defense against Infection

Prashanta Silwal 1,2,*, Jin Kyung Kim 1,2,3, Jae-Min Yuk 4 and Eun-Kyeong Jo 1,2,3, *

1 Department of Microbiology, Chungnam National University School of Medicine, Daejeon 35015, Korea; pst.ktz@gmail.com (P.S.); pcjlovesh6@naver.com (J.K.K.)
2 Infection Control Convergence Research Center, Chungnam National University School of Medicine, Daejeon 35015, Korea
3 Department of Medical Science, Chungnam National University School of Medicine, Daejeon 35015, Korea
4 Department of Infection Biology, Chungnam National University School of Medicine, Daejeon 35015, Korea; yjaemin0@cnu.ac.kr
* Correspondence: hayoung@cnu.ac.kr; Tel.: +82-42-588-8243; Fax: +82-42-585-3686

Received: 27 September 2018; Accepted: 5 November 2018; Published: 6 November 2018

Abstract: 5’-AMP-activated protein kinase (AMPK) plays diverse roles in various physiological and pathological conditions. AMPK is involved in energy metabolism, which is perturbed by infectious stimuli. Indeed, various pathogens modulate AMPK activity, which affects host defenses against infection. In some viral infections, including hepatitis B and C viral infections, AMPK activation is beneficial, but in others such as dengue virus, Ebola virus, and human cytomegaloviral infections, AMPK plays a detrimental role. AMPK-targeting agents or small molecules enhance the antiviral response and contribute to the control of microbial and parasitic infections. In addition, this review focuses on the double-edged role of AMPK in innate and adaptive immune responses to infection. Understanding how AMPK regulates host defenses will enable development of more effective host-directed therapeutic strategies against infectious diseases.

Keywords: AMPK; infection; mycobacteria; host defense

1. Introduction

5’-AMP-activated protein kinase (AMPK) is an intracellular serine/threonine kinase and a key energy sensor that is activated under conditions of metabolic stress [1–3]. It governs a variety of biological processes for the maintenance of energy homeostasis in response to metabolic stresses such as adenosine triphosphate (ATP) depletion [2]. Due to its critical function in metabolic homeostasis, much research has focused on the roles of AMPK in metabolic diseases and cancers [4–6]. However, much less is known about the function of AMPK in infection [7]. Due to the energetic demands of infected cells, most infections by intracellular pathogens are associated with activation of host AMPK, presumably to promote microbial proliferation [8]. AMPK functions as a modulator of host defenses against intracellular bacterial, viral, and parasitic infections [9–12]. Indeed, numerous viruses have the ability to trigger metabolic changes, thereby modulating AMPK activity and substrate selection [13], and AMPK signaling could facilitate or inhibit intracellular viral replication depending on the virus infection [14].

This review focuses on the double-edged role of AMPK in the regulation of host antimicrobial defenses in infections of viruses, bacteria, and parasites. In this review, we describe the existing evidence for the defensive and inhibitory roles of AMPK and the mechanisms underlying its regulation of innate and inflammatory responses. Finally, we describe AMPK-targeting agents that enhance host defenses against infection or control harmful inflammation.
2. Overview of AMPK

5′-AMP-activated protein kinase (AMPK), a serine/threonine kinase, is a key player in bioenergetic homeostasis to preserve cellular ATP [1]. AMPK is activated in response to an increased cellular adenosine monophosphate (AMP)/ATP or adenosine diphosphate (ADP)/ATP ratio, thus promoting catabolic pathways and suppressing biosynthetic pathways [1–3]. Mammalian AMPK exists as a heterotrimeric complex comprising a catalytic subunit α (α1 and α2), a scaffolding β subunit (β1 and β2), and a regulatory γ subunit (γ1, γ2, and γ3) (Figure 1A) [15]. Multiple isoforms of AMPK are encoded by distinct genes of the subunit isotypes, depending on the cell/tissue or species [16]. The AMPK subunit composition and ligand-induced activities of each AMPK isoform complex can differ among cell types, although the α1, β1, and γ1 isoforms are ubiquitously expressed [16,17].

**Figure 1.** Domain structures of the 5′-AMP-activated protein kinase (AMPK) subunits and the mechanisms that regulate activation of AMPK signaling pathways. (A) Conserved domain structure of AMPK subunits consisting of a catalytic α subunit, scaffolding β subunit, and regulatory γ subunit. AID, autoinhibitory domain; CBM, carbohydrate-binding module; CBS, cystathionine-beta-synthase; CTD, C-terminal domain. (B) AMPK is activated by the upstream kinases LKB1, CAMKK2 and TAK1 associated with the canonical pathway (triggered by an increased cellular AMP/ATP ratio) or the non-canonical pathway (triggered by an increased intracellular Ca²⁺ concentration or infection/TLR activation). Activated AMPK modulates cellular homeostasis, such as energy metabolism and autophagy, and mitochondrial homeostasis. (black arrow indicate activation/increase; bar-headed red arrow indicates inhibition/decrease). CAMKK2, calcium/calmodulin-dependent kinase kinase 2; LKB1, liver kinase B1; TAK1, Transforming growth factor-β-activated kinase 1; TLR, Toll-like receptor.
The AMPK α subunit contains a kinase domain at the N terminus, which is activated by phosphorylation of Thr-172 by the major upstream liver kinase B1 (LKB1) [18,19]. In contrast to LKB1, the upstream Ca\(^{2+}\)-calmodulin-dependent kinase kinase (CaMKK) activates AMPK in response to an increased intracellular Ca\(^{2+}\) concentration in the absence of significant changes in ATP/ADP/AMP levels [20]. The regulatory β subunit of AMPK contains a glycogen-binding domain that can sense the structural state of glycogen [21]. Four consecutive cystathionine-β-synthase domains in the regulatory γ subunit are essential for binding to adenosine nucleotides to form an active αβγ complex (Figure 1B) [22,23].

Different AMPK isoforms may have distinct biological functions in different physiological and pathological systems. AMPK governs the cellular energy status by acting as a crucial regulator of energy homeostasis in response to various metabolic stresses, including starvation, hypoxia, and muscle contraction. AMPK activity can be altered by numerous factors, including hormones, cytokines, and nutrients, as well as diverse pathological changes such as metabolic disturbances [24,25]. Because AMPK is important in the adaptation to energy stress, dysregulation of or decreased AMPK activation is implicated in the development of metabolic disorders associated with insulin resistance [6]. In addition to its primary role in the regulation of energy metabolism, AMPK signaling plays a critical role in host–microbial interactions [7]. Furthermore, infections by several viruses result in dysregulation or stimulation of AMPK activity [13]. In mycobacterial infections, AMPK activation promotes activation of host defenses in macrophages and in vivo [12,26]. However, much less is known about the function of AMPK in innate host defenses compared with that in the regulation of metabolism and its mitochondrial function.

3. Multifaceted Role of AMPK in Antimicrobial Responses

Viruses have evolved strategies to manipulate the AMPK signaling pathway to escape host defenses. Indeed, several pathogens can modulate the activity of AMPK/mTOR to obtain sufficient energy for their growth and proliferation [8]. In this review, we discuss microbial manipulation of AMPK activity to affect host defenses against infections. Figure 2 summarizes the multiple roles of AMPK in the viral and bacterial infections addressed in this review. The detailed mechanisms and outcomes of host–pathogen interactions in terms of AMPK modulation are described in Tables 1–4.
3. Multifaceted Role of AMPK in Antimicrobial Responses

Viruses have evolved strategies to manipulate the AMPK signaling pathway to escape host defenses. Indeed, several pathogens can modulate the activity of AMPK/mTOR to obtain sufficient energy for their growth and proliferation [8]. In this review, we discuss microbial manipulation of AMPK activity to affect host defenses against infections. Figure 2 summarizes the multiple roles of AMPK in the viral and bacterial infections addressed in this review. The detailed mechanisms and outcomes of host–pathogen interactions in terms of AMPK modulation are described in Tables 1–4.

![Figure 2](image)

**Figure 2.** Multifaceted roles of AMPK in viral and bacterial infections. A variety of viruses and bacteria modulate host AMPK activity to promote their growth in host cells. Activation of the AMPK signaling pathway has been implicated in both beneficial antiviral (left upper) and detrimental proviral (right upper) responses. In addition, AMPK activation promotes the host response to infections by various bacteria (left lower) but, in some cases, promotes a detrimental response (right lower). The detailed mechanisms by which AMPK activation/inhibition affects infection outcomes are listed in Tables 1–4.

3.1. Roles of AMPK in Viral Infections

3.1.1. Beneficial Effects of AMPK on Virus Infections

Hepatitis C virus (HCV) is a major etiologic agent of chronic liver disease worldwide. HCV infection inhibits AMPKα phosphorylation and signaling [27], and the AMPK agonist metformin suppresses HCV replication in an autophagy-independent manner [28]. Moreover, HCV core protein increases the levels of reactive oxygen species (ROS) and alters the NAD/NADH ratio to decrease the activity and expression of sirtuin 1 (SIRT1) and AMPK, thereby altering the metabolic profile of hepatocytes. This mechanism is implicated in the pathogenesis of hepatic metabolic diseases [29]. As AMPK is a crucial regulator of lipid and glucose metabolism, pharmacological restoration of AMPK activity inhibits lipid accumulation and viral replication in HCV-infected cells [27]. In addition, metformin enhances type I interferon (IFN) signaling by activating AMPK, resulting in inhibition of HCV replication [30]. AMPK inhibition resulted in the downregulation of type I IFN signaling and rescue of the metformin-mediated decrease in the HCV core protein level [30]. Moreover, the AMPK activator 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) inhibits HCV replication by activating AMPK signaling, although the anti-HCV effect of metformin is independent of AMPK activation [31]. In chronic HCV infection, the expression of Sucrose-non-fermenting protein kinase 1/AMP-activated protein kinase-related protein kinase (SNARK), an AMPK-related kinase, is increased to promote transforming growth factor β signaling, which is critical for hepatic fibrogenesis [32]. A more recent study showed that HCV-mediated ROS production triggers AMPK activation to attenuate lipid synthesis and promote fatty acid β-oxidation in HCV-infected cells [33]. These data...
suggest that HCV inhibits AMPK activation to promote its replication, and that the restoration of AMPK activity may be an effective therapeutic modality for HCV infection that acts by metabolic reprogramming or modulation of type I IFN production in host cells [27,28,30,33].

In hepatitis B viral (HBV) infection, AMPK can promote or inhibit viral replication. The detrimental effects of AMPK are described in the following section. Xie et al. reported that AMPK, which is activated by HBV-induced ROS accumulation, suppresses HBV replication [9]. Mechanistically, AMPK activation leads to HBV-mediated autophagic activation, which enhances autolysosome-dependent degradation to restrict viral proliferation [9]. AMPK activity is also involved in the defense against vesicular stomatitis virus, the causal agent of an influenza-like illness, by activating stimulator of IFN genes (STING) [10]. Treatment of mouse macrophages or fibroblasts with an AMPK inhibitor suppressed the production of type I IFN and TNF-α in response to a STING-dependent ligand or agonist, suggesting a role for AMPK in STING signaling [10]. AMPK plays a role in the excessive inflammatory cytokine/chemokine levels in Mint3/Apba3 depletion models of severe pneumonia due to influenza virus [34]. Indeed, food-derived polyphenols, such as epigallocatechin gallate and curcumin, are useful for controlling viral and bacterial infections [35]. Although a review of AMPK-modulating polyphenols is beyond our scope, we highlight the therapeutic promise of polyphenols against infection. For example, curcumin from Curcuma longa inhibits influenza A viral infection in vitro and in vivo, at least in part by activating AMPK [36]. The polyphenol epigallocatechin gallate attenuates Tat-induced human immunodeficiency virus (HIV)-1 transactivation by activating AMPK [37]. Further studies should examine the ability of food-derived polyphenols to activate AMPK signaling to control viral replication in host cells.

Human adenovirus type 36, which is associated with obesity, inhibits fatty acid oxidation and AMPK activity and increases accumulation of lipid droplets in infected cells [38]. The AMPK signaling pathway and its upstream regulator LKB1 repress replication of the bunyavirus Rift Valley Fever virus (RVFV), a re-emerging human pathogen [39]. The mechanisms of the antiviral effects of AMPK on RVFV and other viruses are mediated by AMPK inhibition of fatty acid synthesis [39]. Pharmacologic activation of AMPK suppresses RVFV infection and reduces lipid levels by inhibiting fatty acid biosynthesis [39]. In addition, the AMPK/Sirt1 activators resveratrol and quercetin significantly reduce the viral titer and gene expression, as well as increase the viability of infected neurons, in herpes simplex virus type 1 (HSV-1) infection [40]. Moreover, coxsackievirus B3 (CVB3) infection triggers AMPK activation, which suppresses viral replication in HeLa and primary myocardial cells [41]. The AMPK agonists AICAR and metformin suppress CVB3 replication and attenuate lipid accumulation by inhibiting lipid biosynthesis [41]. Thus, regulation of fatty acid metabolism by AMPK signaling is an essential component of cell autonomous immune responses [39].

Latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) inactivates LKB1/AMPK, whereas AMPK activation by AICAR abrogated LMP1-mediated proliferation and transformation of nasopharyngeal epithelial cells, suggesting therapeutic potential for EBV-associated nasopharyngeal carcinoma [42]. Moreover, constitutive activation of AMPK inhibited lytic replication of Kaposi’s sarcoma-associated herpesvirus in primary human umbilical vein endothelial cells [43]. These data suggest that AMPK suppresses cell transformation and infection-related tumorigenesis in a context-dependent manner. The roles of AMPK in viral infection are listed in Table 1.

3.1.2. Detrimental Effects of AMPK on Virus Infections

Several viruses manipulate AMPK signaling to promote their replication. Genome-scale RNA interference screening of host factors in rotaviral infection identified AMPK as a critical factor in the initiation of a rotavirus-favorable environment [44]. In dengue viral infections, the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGGR) activity elevated by AMPK inactivation resulted in generation of a cholesterol-rich environment in the endoplasmic reticulum, which promoted formation of viral replication complexes [45]. Also, dengue viral infection stimulates AMPK activation to induce proviral lipophagy, thereby enhancing fatty acid β-oxidation and viral replication [46].
## Table 1. Beneficial Effects of AMPK in viral infection.

| Pathogen                     | Small Molecules/Chemicals | Agonist/Antagonist | Involvement of AMPK                                                                 | Outcome (In Vitro/In Vivo)                                      | Ref. |
|------------------------------|---------------------------|--------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------|------|
| Hepatitis C virus (HCV)      | HCV                       | -                  | HCV infection inhibit AMPKa phosphorylation and Akt-TSC-mTORC1 pathway            | AMPK inhibition is required for HCV replication (in vitro)     | [27,28] |
|                              | AICAR, Metformin, A769662 | Agonist            | Restoration of AMPKa activity                                                      | Antiviral effects (in vitro)                                   | [27,28] |
|                              | Metformin                 | Agonist            | Type I interferon signaling through AMPK pathway activation                        | Inhibits HCV replication (in vitro)                            | [30]  |
|                              | AICAR                     | Agonist            | AMPK activation (Indirect effects counteracted by compound C)                     | Suppression of HCV replication (in vitro)                       | [31]  |
|                              | Metformin                 | Agonist            | Type I interferon signaling through AMPK pathway activation                        | Inhibits HCV replication (in vitro)                            | [30]  |
|                              | AICAR                     | Agonist            | AMPK activation (Indirect effects counteracted by compound C)                     | Suppression of HCV replication (in vitro)                       | [31]  |
|                              | AICAR                     | Agonist            | AMPK activation, autophagic flux activation                                        | Inhibits HBV production (in vitro)                             | [9]   |
|                              | Compound C dominant-negative AMPKa | Antagonist | AMPK inhibition                                                                  | Enhances HBV production (in vitro and in vivo)                  | [9]   |
|                              | AICAR                     | Agonist            | STING-dependent signaling activation                                              | Type I IFN production and antiviral responses (in vitro)      | [10]  |
|                              | Compound C                | Antagonist         | Inhibition of STING-dependent signaling                                            | Suppression of IFN-β production (in vitro)                      | [10]  |
|                              | Mint3 depletion           | -                  | AMPK activation                                                                  | Attenuates severe pneumonia by influenza infection (in vivo)   | [34]  |
|                              | AICAR                     | Agonist            | AMPK activation in Mint3 depletion model                                           | Decreases inflammatory cytokine production in Mint3-deficient macrophages (in vivo) | [34]  |
|                              | Curcumin                  | Activator          | AMPK activation                                                                  | Inhibits influenza A virus infection (in vitro and in vivo)    | [36]  |
| Influenza virus              |                           |                    |                                                                                   |                                                                  |       |
| Human immunodeficiency virus-1 | Epigallocatechin gallate | Activator          | AMPK activation                                                                  | Attenuation of Tat-induced human immunodeficiency virus 1 (HIV-1) transactivation | [37]  |
| Human adenovirus             | Adenovirus                | -                  | Inhibit AMPK activity/signaling                                                    | Virus induces lipid droplets, presumably associated with obesity (in vitro) | [38]  |
| Rift Valley Fever Virus (RVFV) | A769662, 2-deoxy-D-glucose (2-DG) | Agonist | LKB1/AMPK signaling activation; Inhibition of fatty acid synthesis               | Restriction of viral infection (in vitro)                      | [39]  |
| Herpes simplex virus type 1 (HSV-1) | AICAR, Resveratrol, Quercetin | Activator/agonist | AMPK/Sirt1 activation                                                             | Reduces viral titer and the expression of viral genes (in vitro) | [40]  |
| Pathogen                          | Small Molecules/Chemicals                  | Agonist/Antagonist | Involvement of AMPK                  | Outcome (In Vitro/In Vivo)                                                                 | Ref. |
|----------------------------------|--------------------------------------------|--------------------|-------------------------------------|-------------------------------------------------------------------------------------------|------|
| Coxsackievirus B3 (CVB3)         | -                                          | -                  | AMPK activation by CVB3             | Restriction of viral replication; reversed by siRNA against AMPK                         | [41] |
|                                  | AICAR, A769662, Metformin                  | Agonist            | AMPK activation                     | Restriction of viral replication; improve the survival rate of infected mice (in vitro and in vivo) | [41] |
| Epstein-Barr virus (EBV)         | LMP1 of EBV                                | -                  | LKB1-AMPK inactivation              | AMPK inactivation leads to proliferation and transformation of epithelial cells associated with EBV infection (in vitro) | [42] |
|                                  | AICAR                                      | Agonist            | AMPK activation                     | Inhibition of proliferation of nasopharyngeal epithelial cells (in vitro)              | [42] |
| Kaposi’s sarcoma-associated herpesvirus (KSHV) | AICAR, Metformin, Constitutive active AMPK | Agonist            | AMPK as a KSHV restriction factor   | Inhibits the expression of viral lytic genes and virion production (in vitro)          | [43] |
|                                  | Compound C, Knockdown of AMPKα1            | Antagonist         | AMPK inhibition                     | Enhances viral lytic gene expression and virion production (in vitro)                 | [43] |
In HBV infection, the HBV X protein activates AMPK, and inhibition of AMPK reduces HBV replication in rat primary hepatocytes [47]. Inhibition of AMPK led to activation of mTORC1, which is required for inhibition of HBV replication in the presence of low AMPK activity [47]. The crosstalk between AMPK and mTORC1 may enable development of therapeutics that suppress HBV replication and thus also hepatocellular carcinoma (HCC) development [47]. However, as described in Section 3.1.1, AMPK activation by AICAR inhibits extracellular HBV production in HepG2 cells [9]. The discrepancy may be attributed to the use of different cell lines in the two studies [9,47]. Further work should address the role of AMPK in HBV infection in vitro and in vivo. In infection by Zaire Ebolavirus (EBOV), the expression levels of the γ2 subunit of AMPK are correlated with EBOV transduction in host cells. In mouse embryonic fibroblasts treated with a small-molecule inhibitor of AMPK (compound C), it was shown that AMPK activity is required for EBOV replication in host cells and EBOV glycoprotein-mediated entry/uptake [48]. In addition, Avian reoviral infection upregulates AMPK phosphorylation, which leads to activation of mitogen-activated protein kinase (MAPK) p38 in Vero cells, which enhances viral replication [49]. The nonstructural protein p17 of avian reovirus positively regulates AMPK activity, inducing autophagy and increasing viral replication [50].

In HSV-1 infection, the activated AMPK/Sirt1 axis inhibits host-cell apoptosis during early-stage infection, which promotes viral latency and protects neurons [51]. However, during the later stages of infection, HSV-1 induces apoptosis of host cells concomitantly with Sirt1 activation [51]. In HIV-infected cocaine abusers, AMPK signaling plays a role in energy deficit and neuronal dysfunction, which are associated with the development of neuroAIDS [52]. These data suggest that differential regulation of AMPK signaling is a determinant of the viral infection course.

Using a kinome-profiling approach, AMPK and related kinases were found to be effectors of human cytomegalovirus (HCMV) replication [53,54]. HCMV infection induces AMPK and CaMKK2 (upstream activator of AMPK)-dependent remodeling of core metabolism, both of which are required for optimal yield and replication of HCMV [53,54]. Notably, inhibition of AMPK activity by short-interfering RNA-mediated AMPK knockdown or an AMPK antagonist (compound C) prevents viral gene expression, providing valuable insight into the mechanisms of HCMV infection [53]. In addition, the AMPK activation-dependent modulation by HCMV of host-cell metabolism is associated with HCMV replication [55]. HCMV-mediated AMPK activation is dependent on CaM KK, and inhibition of AMPK activity abrogated HCMV replication and DNA synthesis [55]. Furthermore, the cardiac glycoside digitoxin induces phosphorylation of AMPK/ULK1, whereas it suppresses mTOR activity to increase autophagic flux and inhibit HCMV replication [56]. Moreover, HCMV induces production of the host protein viperin [57], which is required for AMPK activation, transcriptional activation of GLUT4 and lipogenic enzymes, and lipid synthesis [58]. The enhanced lipid synthesis promotes formation of the viral envelope and production of HCMV virions [58].

In infection, host-cell autophagy plays an important role in host defense and virus survival. Several viruses can manipulate or subvert the autophagic machinery to favor viral replication. For example, respiratory syncytial virus activates autophagy via the AMPK/mTOR signaling pathway to enhance its replication by inhibiting host-cell apoptosis [59]. Bluetongue virus, a double-stranded segmented RNA virus, also induces host-cell autophagy by activating AMPK [60]. Moreover, AMPK is an upstream regulator of rhabies virus-induced incomplete autophagy to provide the scaffolds for viral replication [61]. In Sendai viral infection, AMPK activity is required for autophagic initiation to promote viral replication [62]. In oncogenic EBV infection, the increased cell survival caused by AMPK-mediated autophagic activation maintains early hyperproliferation of infected cells [63]. These data suggest AMPK activity to be a therapeutical target for the development of novel antiviral agents.

Importantly, type I IFN, a critical effector in the antiviral response, attenuates AMPK phosphorylation and increases the intracellular ATP level [64]. In addition, IFN-β-mediated glycolytic metabolism is important for the acute phase of the antiviral response to CVB3 [64]. The antiviral cytokine IFN-β regulates host-cell metabolism to enhance glucose uptake and ATP generation, which promote the antiviral response [64]. In infection by snakehead vesiculovirus, miR-214 targeting AMPK
suppressed viral replication and upregulated IFN-α expression [65]. Thus, regulation of AMPK activity by the host–pathogen interaction mediates diverse metabolic effects, which modulate viral replication and the host defense response. The beneficial and detrimental effects of AMPK on viral infections are summarized in Tables 1 and 2, respectively.

3.2. Bacterial Infections and AMPK Activation

Intracellular pathogens manipulate the AMPK signaling pathway to alter their metabolic environment to favor bacterial survival or pathogenesis. Mitochondrial dysfunction triggers AMPK signaling, thus enhancing the proliferation of *Legionella pneumophila*, a respiratory pathogen, in *Dictyostelium* cells [66]. Inhibition of AMPK activation reversed the increased *Legionella* proliferation in host cells with mitochondrial disease [66]. However, the AMPK activator metformin triggers mitochondrial ROS generation and activates the AMPK signaling pathway to enhance the host response to *L. pneumophila* in macrophages and promote survival in a murine model of *L. pneumophila* pneumonia [67]. Thus, the role of AMPK activation in bacterial infections differs depending on the host species.

*Salmonella typhimurium* degrades SIRT1/AMPK to evade host xenophagy [68]. In addition, cytosolic *Salmonella* is ubiquitinated and targeted for xenophagy by AMPK activation [69,70]. AMPK activation by AICAR induces autophagy and colocalization of *Salmonella*-containing vacuoles with LC3 autophagosomes [68], whereas inhibition of AMPK by compound C increases bacterial replication by suppressing autophagy [69]. In *Salmonella*-infected cells, AMPK activation is mediated through toll-like receptor-activated TGF-β-activated kinase 1 (TAK1) [69] which is a direct upstream kinase of AMPK in addition to LKB1 and CaMKK2 [71]. In *Brucella abortus* infection, AMPK activation enhances intracellular growth of *B. abortus* by inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-mediated ROS generation [72]. In models of *Escherichia coli* sepsis, ATP-induced pyroptosis is blocked by piperine, a phytochemical present in black pepper (*Piper nigrum* Linn) [73]. The inhibitory effects of piperine on pyroptosis and systemic inflammation are mediated by regulation of the AMPK signaling pathway, as shown by suppression of ATP-mediated AMPK activation by piperine treatment in vitro and in vivo [73]. These data suggest that AMPK plays multiple roles in bacterial infections.

AMPK activation promotes host defenses against infections by several microbes. Transcriptomic and proteomic analyses of a *Caenorhabditis elegans* model indicated that AMPKs function as regulators and mediators of the immune response to infection by, for example, *Bacillus thuringiensis* [74]. Several small-molecule AMPK activators exert protective effects against *Helicobacter pylori*-induced apoptosis of gastric epithelial cells [70,75]. The AMPK agonists A-769662 and resveratrol, as well as AMPKα overexpression, inhibit apoptosis in *H. pylori*-infected gastric epithelial cells [76]. The AMPK activator compound 13 ameliorates *H. pylori*-induced apoptosis of gastric epithelial cells by modulating ROS levels via the AMPK-heme oxygenase-1 axis [76]. Blockade of AMPK signaling significantly abrogates the protective effect of compound 13 against *H. pylori* within gastric epithelial cells [76].

Metformin and AICAR repress infection by *Pseudomonas aeruginosa*, an important opportunistic pathogen, of airway epithelial cells by inhibiting bacterial growth and increasing transepithelial electrical resistance [77]. AMPKα1 depletion increased the susceptibility to *Staphylococcus aureus* endophthalmitis in mice [78], suggesting a protective role for AMPK in bacterial retinal inflammation. Moreover, AMPK activation by AICAR enhances its anti-inflammatory effects, phagocytosis, and bactericidal activity against *S. aureus* infection of various phagocytic cells including microglia, macrophages, and neutrophils [78]. Epigallocatechin gallate, a polyphenol in green tea, inhibits the viability of *Propionibacterium acnes*, a pathogen associated with acne, and exerted an antilipogenic effect in SEB-1 sebocytes by activating the AMPK/sterol regulatory element-binding protein pathway [35]. Moreover, *Acinetobacter baumannii*, an emerging opportunistic pathogen, activates autophagy via the AMPK/ERK/mTOR pathway to promote an antimicrobial response to intracellular *A. baumannii* [79]. The roles of AMPK in bacterial infection are summarized in Table 3.
Table 2. Detrimental Effects of AMPK in viral infection.

| Pathogen                        | Small Molecules/Chemicals | Agonist/Antagonist | Involvement of AMPK                                                                 | Outcome (In Vitro/In Vivo)                  | Ref.  |
|---------------------------------|---------------------------|--------------------|-----------------------------------------------------------------------------------|---------------------------------------------|-------|
| Rotavirus                       | RNAi                      | -                  | AMPK-mediated glycolysis, fatty acid oxidation and autophagy                      | Development of a rotavirus replication-permissive environment (in vitro) | [44]  |
|                                 | AICAR, Metformin           | Agonist            | AMPK activation (AICAR, directly; Metformin, indirectly)                          | Upregulation of the proportion of viral infected cells (in vitro) | [44]  |
|                                 | Dorsomorphin               | Inhibitor          | Inhibition of AMPK activity                                                      | Reduces the number of infected cells (in vitro) | [44]  |
| Dengue virus                    | Virus infection            | -                  | Elevates 3-hydroxy-3-methylglutaryl-CoA reductase activity through AMPK inactivation | Promotes the formation of viral replicative complexes (in vitro) | [45]  |
|                                 | Metformin, A769662         | Agonist            | AMPK activation                                                                  | Antiviral effects (in vitro)                | [45]  |
|                                 | Compound C                 | Antagonist         | AMPK inhibition                                                                   | Augments the viral genome copies (in vitro) | [45]  |
|                                 | Virus infection            | -                  | AMPK activation; induction of lipophagy                                           | Increases viral replication (in vitro)       | [46]  |
|                                 | Compound C siRNA against AMPKa1 | Antagonist      | Inhibition of proviral lipophagy                                                  | Decreases viral replication (in vitro)       | [46]  |
| Hepatitis B virus (HBV)         | HBs protein                | -                  | Decreased ATP, activates AMPK in rat primary hepatocytes                           | AMPK inhibition decreases HBV replication (in vitro) | [47]  |
|                                 | Compound C                 | Antagonist         | Activates mTORC1                                                                  | Reduces HBV replication (in vitro)           | [47]  |
| Ebola virus                     | Compound C                 | Antagonist         | Less permissive to Ebola virus infection (Similar effects in AMPKa1- or AMPKa2-deleted mouse embryonic fibroblasts) | Inhibits EBOV replication in Vero cells (in vitro) | [48]  |
| Avian reovirus                  | Virus infection            | -                  | Upregulates AMPK phosphorylation leading to p38 MAPK activation                   | Increases virus replication (in vitro)       | [49]  |
|                                 | P17 protein                | -                  | P17 protein activates AMPK to induce autophagy                                    | Increases virus replication (in vitro)       | [50]  |
|                                 | AICAR                      | Agonist            | AMPK activation (Indirect effects through p38 MAPK)                               | Increases virus replication (in vitro)       | [49]  |
|                                 | Compound C                 | Antagonist         | AMPK inhibition                                                                   | Decreases virus replication (in vitro)       | [49]  |
| Herpes simplex virus type 1 (HSV-1) | HSV-1                      | -                  | In early infection, AMPK is down-regulated, and then recovered gradually          | AMPK/Sirt1 axis inhibits host apoptosis in early infection (in vitro) | [51]  |
| Human immunodeficiency virus-1 (HIV1) | Cocaine                  | -                  | Induces AMPK upregulation; AMPK plays a role in energy deficit and metabolic dysfunction | Cocaine exposure during HIV infection accelerates neuronal dysfunction (in vitro) | [52]  |
| Pathogen                        | Small Molecules/Chemicals | Agonist/Antagonist | Involvement of AMPK                                                                 | Outcome (In Vitro/In Vivo)                                                                 | Ref.   |
|--------------------------------|--------------------------|--------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------|
| Human cytomegalovirus (HCMV)   | siRNA to AMPK            | Antagonist         | Interferes with normal accumulation of viral proteins and alters the core metabolism | Compound C inhibits the viral production of HCMV (in vitro); blocks the immediate early phase of viral replication (in vitro) | [53,54]|
|                                |                          |                    |                                                                                   | RNA-based inhibition of AMPK attenuates HCMV replication (in vitro)                       | [55]   |
|                                | Digitoxin                | Activator          | Digitoxin modulates AMPK-ULK1 and mTOR activity to increase autophagic flux         | Viral inhibition (in vitro)                                                              | [56]   |
|                                | Digitoxin + AICAR         |                    | Combination reduces autophagy                                                      | Viral replication (in vitro)                                                              | [56]   |
| Respiratory syncyntial virus (RSV) | RNAi to AMPK           |                    | blocks glycolytic activation in HCMV-infected cells                                |                                                                                          |        |
| Bluetongue virus               | Rabies virus             |                    | Induces autophagy through activation of AMPK                                       | Favors viral replication (in vitro)                                                      | [60]   |
|                                | Rabies virus             |                    | Incomplete autophagy induction via CASP2-AMPK-MAPK1/3/11-AKT1-mTOR pathways         | Enhances viral replication (in vitro)                                                    | [61]   |
| Sendai virus                   | Sendai virus             |                    | Induces host protein TDRD7, an inhibitor of autophagy-inducing AMPK                 | Host autophagy and viral replication is inhibited by TDRD7 (in vitro)                    | [62]   |
|                                | Compound C, shRNA to AMPK| Antagonist         | Inhibition of AMPK activity; inhibits viral protein                               | AMPK activity is required for viral replication (in vitro)                              |        |
| Snakehead vesiculo-virus       | Snakehead vesiculo-virus |                    | Downregulates miR-214, which targets AMPK                                         | AMPK upregulation promotes viral replication through reduction of IFN-α expression (in vitro) | [65]   |
| Pathogen          | Small Molecules/Chemicals | Agonist/Antagonist | Involvement of AMPK                                                                 | Outcome (In Vitro/In Vivo)                        | Ref.  |
|-------------------|---------------------------|--------------------|-------------------------------------------------------------------------------------|---------------------------------------------------|-------|
| *L. pneumophila*  | -                         | -                  | Chronic AMPK activation involved in host susceptibility to infection (Direct effects by AMPKα antisense) | Bacterial multiplication in host cells with mitochondrial dysfunction | [66]  |
|                   | Metformin                 | Agonist            | Bactericidal effects are mediated by mitochondrial ROS production (Indirect)          | Antimicrobial responses (in vitro and in vivo)     | [67]  |
|                   |                           |                    |                                                                                      |                                                   |       |
| *S. typhimurium*  | -                         | -                  | *S. typhimurium* exhibits virulence through lysosomal degradation of SIRT1 and AMPK to impair autophagy | Bacterial evasion from autophagic clearance (in vitro) | [68]  |
|                   | AICAR                     | Agonist            | Upregulation of autophagy                                                             | Increased colocalization of salmonella containing vacuole with LC3 (in vitro) | [68]  |
|                   |                           |                    |                                                                                      | Autophagy activation (in vitro)                    | [69]  |
|                   | Compound C                | Antagonist         | AMPK inhibition                                                                       | Increased bacterial replication by suppression of autophagy (in vitro) | [69]  |
| *B. abortus*      | -                         | -                  | AMPK activation via inositol-requiring enzyme 1 (IRE1)                                | Promote intracellular growth of *B. abortus* (in vitro) | [72]  |
|                   | Compound C                | Antagonist         | AMPK inhibition; activation of NADPH oxidase-mediated ROS production                  | Suppression of intracellular growth (in vitro)     | [72]  |
| *E. coli*         | Piperine                  | Antagonist         | Inhibits ATP-induced pyroptosis by suppressing AMPK activation                          | Inhibition of pyroptosis; attenuation of systemic inflammation (in vitro and in vivo) | [73]  |
|                   | ATP Metformin             | Agonist            | AMPK activation; increases pyroptosis by inflammasome activation                      | Activation of pyroptosis (in vitro)                | [73]  |
| *B. thuringiensis*| -                         | -                  | AMPK identified by transcriptome and proteome data analysis in vivo (Indirect)         | Potentially related to regulation of immune defense (Not determined) | [74]  |
| *H. pylori*       | A-769662 Resveratrol      | Agonist            | Inhibits *H. pylori*-induced apoptosis (Direct effects by overexpression of AMPKα)    | Alleviates *H. pylori*-induced gastric epithelial cell apoptosis (in vitro) | [75]  |
|                   | Compound 13               | Agonist            | Inhibits *H. pylori*-induced apoptosis through AMPK-heme oxygenase-1 signaling        | Alleviates *H. pylori*-induced gastric epithelial cell apoptosis (in vitro) | [76]  |
|                   | Compound C                | Antagonist         | Inhibitory effects upon compound 13-mediated anti- *H. pylori* activities (Direct effects by AMPKα1 shRNAs) | Aggravates *H. pylori*-induced gastric epithelial cell apoptosis (in vitro) | [76]  |
| *P. aeruginosa*   | AICAR Metformin           | Agonist            | Counteracts the bacterial effects on the reduction of transepithelial electrical resistance (Indirect effects) | Inhibits hyperglycemia-induced bacterial growth; Improve airway epithelial barrier function (in vitro) | [77]  |
Table 3. Cont.

| Pathogen                  | Small Molecules/Chemicals | Agonist/Antagonist | Involvement of AMPK                                                                 | Outcome (In Vitro/In Vivo)                                                                 | Ref.  |
|---------------------------|---------------------------|--------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------|
| *S. aureus*               | AICAR                     | Agonist            | AMPK activation                                                                   | Reduces bacterial burden and intraocular inflammation; Increases bacterial killing in macrophages (in vitro and in vivo) | [78]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
|                           | Compound C                | Antagonist         | Downregulates AMPK activity (Direct effects by AMPKα1 knockout mice)               | Counteracts AICAR-mediated anti-inflammatory effects (in vivo); Increases susceptibility towards *S. aureus* endophthalmitis (in vivo) | [78]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
| *P. acne*                 | Epigallocatechin gallate  | -                  | Activates AMPK-sterol regulatory element-binding proteins pathway activation       | Anti-lipogenic effects in SEB-1 sebocytes (in vitro)                                       | [35]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
| *A. baumannii*            | -                         | -                  | Activates autophagy through Beclin-1-dependent AMPK/ERK/mTOR pathway (Indirect effects by different *A. baumannii* strains) | Autophagy may promote antimicrobial responses (in vivo)                                    | [79]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
| *M. tuberculosis*         | Metformin                 | Agonist            | AMPK activation; Increased mtROS production; Increases phago-lysosomal fusion (Direct effects upon bacterial growth in vitro) | Inhibition of intracellular growth of *M. tuberculosis* (drug-resistant strain; in vitro); Increases the efficacy of conventional TB drugs in vivo | [80]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
|                           | AICAR                     | Agonist            | AMPK-PPARGC1A signaling-mediated autophagy activation; Enhancement of phagosomal maturation (Direct effects by shRNA against AMPKα) | Upregulation of antimicrobial responses (in vitro and in vivo)                             | [12]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
|                           | Compound C                | Antagonist         | Counteracts the effects by AICAR upon intracellular inhibition of *M. tuberculosis* growth | Downregulation of antimicrobial responses (in vitro)                                       | [12]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
|                           | Vitamin D (1,25-D3)       | -                  | Induces autophagy through LL-37 and AMPK activation (Indirect effects upon LL-37 function) | Promotes autophagy and antimicrobial response in human monocytes/macrophages (in vitro)     | [81]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
|                           | Phenylbutyrate Vitamin D  | -                  | Induces LL-37-mediated autophagy (Indirect effects; AMPK is involved in LL-37-mediated autophagy) | Improves intracellular killing of *M. tuberculosis* (in vitro)                             | [82]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
|                           | Gamma-aminobutyric acid (GABA) | Agonist       | Induces autophagy (Direct effects by shRNA against AMPK)                           | Promotes antimicrobial effects against *M. tuberculosis* (in vitro and in vivo)            | [83]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
|                           | Ohmyungsamycins           | -                  | Activates AMPK and autophagy; Intracellular inhibition of bacterial growth; Amelioration of inflammation (Indirect effects upon host autophagy) | Promotes antimicrobial effects against *M. tuberculosis* (in vitro and in vivo)            | [26]  |
|                           |                           |                    |                                                                                   |                                                                                          |       |
|                           | Compound C                | Antagonist         | Blocks the secretion of neutrophil Matrix metalloproteinase-8 (MMP-8)             | Neutrophil MMP-8 secretion is related to matrix destruction in human pulmonary TB (in vitro and in human TB lung specimens) | [84]  |
3.3. Roles of AMPK in Mycobacterial Infection

The seminal study by Singhal et al. addressed the effect of metformin as an adjunctive therapy for tuberculosis. Importantly, metformin suppressed the intracellular growth of *Mycobacterium tuberculosis* (*Mtb*) in vitro, including drug-resistant strains, by activating the AMPK signaling pathway [80]. In vivo, metformin attenuated the immunopathology and enhanced the immune response and showed a synergistic effect with conventional anti-TB drugs in *Mtb*-infected mice [80]. The microbicidal effect of metformin in macrophages is due, at least in part, to mitochondrial ROS generation, which is associated with AMPK signaling [80]. Type 2 diabetes mellitus (DM) is re-emerging as a risk factor for human tuberculosis, thus candidate host directed therapeutic targets for tuberculosis combined with DM should be identified [85]. Human cohort studies showed that metformin treatment for DM is associated with a decreased prevalence of latent tuberculosis compared with alternative DM treatments, suggesting metformin to be a candidate HDT for tuberculosis patients with type 2 DM [80,85]. Indeed, *Mtb* infection inhibits AMPK phosphorylation but increases mTOR kinase activation in macrophages [12]. The AMPK activator AICAR via autophagic activation enhances phagosomal maturation and antimicrobial responses in macrophages in *Mtb* infection [12]. In human monocytes/macrophages, vitamin D-mediated antimicrobial responses are mediated by the antimicrobial peptide LL-37 via AMPK activation [81]. In addition, LL-37-induced autophagy by phenylbutyrate, alone or in combination with vitamin D, promotes intracellular killing of *Mtb* in human macrophages via AMPK- and PtdIns3K-dependent pathways [82]. Recent findings revealed the role of gamma-aminobutyric acid (GABA) in AMPK activation to enhance the autophagy and the antimicrobial responses [83]. Silencing of AMPK by a lentiviral short hairpin RNA (shRNA) specific to AMPK reduces GABA-induced autophagic activation as well as phagosomal maturation during *Mtb* infection [83].

MicroRNAs are small non-coding RNAs involved in the regulation of diverse physiological and pathological processes, including *Mtb* infection. Mycobacterial infection of macrophages upregulates miR-33 and miR-33*, which target and suppress AMPKα [86]. Interestingly, miR-33/miR-33* regulates autophagy by suppressing AMPK-dependent activation of the transcription of autophagy- and lysosome-related genes and promoting accumulation of lipid bodies in *Mtb* infection [86]. *Mtb* infection increases the expression of MIR144*/has-miR-144-5p, which targets DNA damage regulated autophagy modulator 2 (DRAM2), to inhibit the antimicrobial responses to *Mtb* infection in human monocytes/macrophages. In contrast, autophagic activators enhance production of the autophagy-related protein DRAM2 by activating the AMPK signaling pathway; this contributes to host defenses against *Mtb* in human macrophages [87].

Although AMPK may play a protective role in tuberculosis, it has also been reported to exert an immunopathological effect by driving the secretion of neutrophil matrix metalloproteinase-8 (MMP-8), resulting in matrix destruction and cavitation, which enhance the spread of *Mtb* [84]. Neutrophil-derived MMP-8 secretion is upregulated in *Mtb* infection and neutrophils from AMPK-deficient patients express lower levels of MMP-8, suggesting a key role for MMP-8 in tuberculosis immunopathology [84]. Because the pathogenesis of tuberculosis is complex, further information on the function of AMPK in the immune response to *Mtb* infection is needed for development of improved therapeutic strategies [88]. The roles of AMPK in mycobacterial infection are listed in Table 3.

3.4. Roles of AMPK in Parasite Infections

The immune response to parasitic helminths involves M2-type cells, CD4(+) Th2 cells, and group 2 innate lymphoid cells. AMPK activation regulates type 2 immune responses and ameliorates lung injury in response to hookworm infections [89]. Mice deficient in AMPK α1 subunit exhibited impaired type 2 responses, an increased intestinal worm burden, and exacerbated lung injury [89]. In *Leishmania*-infected macrophages, *Leishmania infantum* causes a metabolic switch to enhance oxidative phosphorylation by activating LKB1/AMPK and SIRT1 [90]. Impairment of metabolic...
reprogramming by SIRT1 or AMPK suppresses intracellular growth of the parasite, suggesting a role for AMPK/SIRT1 in intracellular proliferation of *L. infantum* [90]. In *Schistosoma japonicum* egg antigen (SEA)-mediated autophagy, which is modulated by IL-7 and the AMPK signaling pathway, ameliorate liver pathology, suggesting AMPK to be a therapeutic target factor for schistosomiasis [91].

Notably, host AMPK activity is decreased by hepatic *Plasmodium* infection. Activation of the AMPK signaling pathway by AMPK agonists, including salicylate, suppresses the intracellular replication of malaria parasites, including that of the human pathogen *Plasmodium falciparum* [92]. These data suggest that host AMPK signaling is a therapeutic target for hepatic *Plasmodium* infection [92]. In addition, resveratrol protects cardiac function and reduces lipid peroxidation and trypanosomal burden in the heart by activating AMPK, suggesting a role for AMPK in Chagas heart disease [93]. The roles of AMPK in parasitic infections are listed in Table 4.

**Table 4.** The role of AMPK in parasitic infection.

| Pathogen            | Small Molecules/Chemicals | Agonist/Antagonist | Involvement of AMPK (Direct/Indirect)                                                                 | Outcome (In Vitro/In Vivo)                                                                 | Ref. |
|---------------------|---------------------------|--------------------|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|------|
| Hookworm            |                           |                    | AMPKα1 deficiency inhibit IL-13 and CCL17, and defective type 2 immune resistance (Direct effects using by AMPKα1 knockout mice) | AMPKα1 suppresses lung injury and drives M2 polarization during infection                  | [89] |
| *Nippostrongylus brasiliensis* | -                      |                    | Infection leads to a metabolic switch to activate AMPK through the SIRT1-LKB1 axis (Direct effects using by AMPKα1 knockout mice) | Ablation of AMPK promotes parasite clearance in vitro and in vivo                          | [90] |
| *L. infantum*       |                           |                    | Infection-driven IL-7-IL-7R signaling inhibits autophagy; IL-7 inhibits macrophage autophagy via AMPK | Anti-autophagic IL-7 increases liver pathology (in vivo)                                    | [91] |
| *S. japonicum*      | Metformin                 | Agonist            | Decreases the autophagosome formation in macrophages                                                  | in vitro                                                                                 |      |
|                     | Compound C                | Antagonist         | Increases autophagosome formation in macrophages (Direct effects by siAMPKα)                         | in vitro                                                                                 |      |
| *P. falciparum*     | Salicylate Metformin A769662 | Agonist           | AMPK activity is suppressed upon infection                                                            | Decreases Plasmodium hepatic growth                                                       | [92] |
| *Trypanosoma cruzi*| Resveratrol, Metformin    |                    | AMPK activation impairs the intracellular replication of malaria                                      | Antimalarial interventions (in vitro and in vivo)                                          |      |

3.5. AMPK in Fungal Infection

A recent phosphoproteomic analysis of *Cryptococcus neoformans* (Cn) infection showed that AMPK activation is triggered by fungal phagocytosis and is required for autophagic induction. Interestingly, AMPK depletion in monocytes promoted host resistance to fungal infection in mouse models, suggesting that AMPK represses the immune response to *Cryptococcus* infection [94].
4. Roles of AMPK in Innate and Adaptive Immune Responses

The roles of AMPK in modulation of the mitochondrial network and energy metabolism, which are associated with the immune response, have been investigated [95]. Here, we briefly review recent data on AMPK regulation of innate and adaptive immune responses in infection and inflammation. Figure 3 summarizes the regulatory roles and mechanisms of a variety of small-molecule AMPK activators in terms of innate immune and inflammatory responses.

The data must be interpreted cautiously, as the small-molecule activators (e.g., AICAR, metformin, and compound C) function via off-target mechanisms, such as AMPK-independent pathways or inhibition of protein kinases other than AMPK [31,96,97]. The beneficial effects of these compounds remain to be fully determined. Thus, selective compounds such as MK-8722 [98] and SC4 [99] and the selective inhibitor SBI-0206965 [100] should be considered for future AMPK-targeted treatment strategies.

**Figure 3.** Regulatory effects and underlying mechanisms of small-molecule AMPK activators on the innate immune and inflammatory responses. (red upward arrows indicate activation/increase and blue downward arrows indicate inhibition/decrease)

### 4.1. Role of AMPK in Regulation of the Innate Immune Response

AMPK is involved in regulation of the innate immune response. For example, the innate-immune stimulator toll-like receptor (TLR) 9 inhibits energy substrates (intracellular ATP levels) and activates AMPK, which enhances stress tolerance in cardiomyocytes and neurons, while stimulation by the TLR9 ligand induces inflammation [101]. The AMPK activator AICAR suppresses the lung inflammation induced by lipoteichoic acid, a major component of the cell wall of Gram-positive bacteria [102]. Natural killer (NK) cells are crucial in the innate immune response to viral infections and transformed cells. Activation of the AMPK signaling pathway or inhibition of mTOR is associated with enhanced

**Table of Small-Molecule AMPK Activators**

| Activator | Effects | Sources |
|-----------|---------|---------|
| Metformin | Inhibits inflammatory responses and injury of multiple organs | [108] |
| LPS-induced inflammatory responses | [116] |
| AICAR | Lung inflammation induced by lipoteichoic acid | [103] |
| LPS-induced acute lung injury | [107] |
| LPS-induced endothelial hyperpermeability | [113] |
| Inflammatory responses in CNS and acute lung injury in sepsis | [117] |
| Palmitate-induced NLRP3 inflammasome, IL-1β production | [127] |
| SB216763 | Severity of acute lung injury | [118] |
mitophagy and an increased number of memory NK cells in antiviral responses [103]. In contrast, increased expression of the inhibitory killer cell lectin-like receptor G1 in aged humans is related to AMPK activation, which has been implicated in disruption of NK cell function [104]. In addition, AMPK activation contributes to CD1d-mediated activation of NK T cells, an important cell type in the innate immune response [105]. The findings above suggest that AMPK plays a pleiotropic role in the regulation of the innate immune response depending on the stimulus and cell type in question.

4.2. AMPK Regulation of Local and Systemic Inflammation

AMPK activators enhance neutrophil chemotaxis, phagocytosis, and bacterial killing to protect against peritonitis-induced sepsis [106]. Indeed, AMPK activators including metformin inhibit injurious inflammatory responses, including neutrophil proinflammatory responses and injury to multiple organs such as the lung, liver, and kidney [107–109]. Pharmacologic activation of AMPK by metformin, berberine, or AICAR dampens excessive TLR4/NF-κB signaling, M2-type macrophage polarization, and the production of proinflammatory mediators in vitro and in models of sepsis [110–115]. The anti-inflammatory effect of metformin in mice with lipopolysaccharide (LPS)-induced septic shock and in ob/ob mice is mediated at least in part by AMPK activation [116]. In septic mice, AMPK activation by AICAR or metformin reduces the severity of sepsis-induced lung injury, enhances AMPK phosphorylation in the brain, and attenuates the inflammatory response [117,118].

Treatment with trimetazidine protects against LPS-induced myocardial dysfunction, exerts an anti-apoptotic effect, and attenuates the inflammatory response due to its effect on the SIRT1/AMPK pathway [119]. Moreover, the flavonoid naringenin dampens inflammation in vitro and protects against murine endotoxemia in vivo; these effects are mediated by AMPK/ATF3-dependent inhibition of the TLR4 signaling pathway [120]. In severe acute HBV infection, halofuginone, a plant alkaloid, inhibits viral replication by activating AMPK-mediated anti-inflammatory responses [121]. AMPK activation also enhances the phagocytic capacities of neutrophils and macrophages [122]. Transient receptor potential melastatin 2, an oxidant sensor cation channel, promotes extracellular trap formation by neutrophils via the AMPK/p38 MAPK pathway, enhancing their antimicrobial activity [123]. AMPK activation not only modulates the acute inflammatory response but also promotes neutrophil-dependent bacterial uptake and killing [106].

In perinatal hypoxic–ischemic encephalopathy, prolonged activation of AMPK signaling suppresses the response to oxygen/glucose deprivation and promotes neonatal hypoxic–ischemic injury [124]. Although AMPK inhibition increases neuronal survival, blockade of AMPK prior to oxygen/glucose deprivation increases cell damage and death [124]. Therefore, the clinical implications of AMPK activation are complex, and further preclinical and clinical data are needed to enable therapeutic use of AMPK activators in patients with acute or chronic inflammation.

4.3. Role of AMPK in Inflammasome Activation

AMPK is implicated in modulation of NLRP3 inflammasome activation. The bactericidal activity of the isoquinoline alkaloid berberine exerts a bactericidal effect by augmenting inflammasome activation via AMPK signaling [125]. However, metformin increases mortality of mice with bacteria, likely via an AMPK-mediated increase in ATP-induced inflammasome activation and pyroptosis [126].

AMPK is implicated in the inhibition of palmitate-induced inflammasome activation [127]. The AMPK activator AICAR inhibits palmitate-induced activation of the NLRP3 inflammasome and IL-1β secretion by suppressing ROS generation [127]. In addition, NLRP3 inflammasome activation and production of IL-1β are upregulated in the peripheral mononuclear cells of drug-naïve type-2 diabetic patients, suggesting a role of the inflammasome in the pathogenesis of type-2 diabetes [128]. Interestingly, AMPK activation is responsible for the significantly reduced mature IL-1β level in peripheral myeloid cells from type-2 diabetic patients after two months of metformin therapy [128]. In a model of hyperalgesia, which is associated with NLRP3 inflammasome
activation, metformin attenuated the clinical symptoms and improved the biochemical parameters, whereas blockade of AMPK activation by compound C provoked hyperalgesia and increased the levels of IL-1β and IL-18 [129]. Furthermore, pharmacological activation of AMPK inhibits the monosodium urate (MSU) crystal-induced inflammatory response, suggesting a role for AMPK in gouty inflammation. Moreover, colchicine, an inhibitor of microtubule assembly used to treat gouty arthritis, enhances AMPKα-mediated phosphorylation, thereby inhibiting inflammasome activation and IL-1β release [130]. Further studies on the efficacy of AMPK activators against inflammasome-associated diseases are thus warranted.

4.4. Role of AMPK in the Regulation of the Adaptive Immune Responses

AMPKα1 is a key regulator of the adaptive immune response, particularly T helper (Th1) and Th17 cell differentiation and the T-cell responses to viral and bacterial infections [131]. In addition, in models of simian immunodeficiency viral infection, AMPK activation is associated with the virus-specific CD8(+) cytotoxic T-lymphocyte population and control of Simian Immunodeficiency Virus (SIV) [132]. The mechanism(s) by which AMPK signaling activates innate and adaptive immune responses and controls excessive inflammation must be determined if the potential of AMPK-targeted therapy is to be realized.

5. Conclusions

Although much research has focused on the role of AMPK in the regulation of mitochondrial and metabolic homeostasis, several issues remain to be addressed. Further work should focus on the mechanism(s) by which AMPK modulates host defenses against infections in vivo. Several pathogens modulate the host metabolic environment to promote their survival and replication. Because of its role in regulating mitochondrial metabolism, dynamics, and biogenesis, AMPK signaling can provide energy to the pathogen and/or host, benefitting either. Stimulation of AMPK activity enhances host defenses against diverse viruses, bacteria, and parasites, notably Mtb. Moreover, AMPK links the innate and adaptive immune responses to infection. However, the molecular mechanisms underlying AMPK regulation of innate and adaptive immunity are unclear. AMPK-targeted small molecules have potential as antimicrobial agents as well as metabolic drugs. Further work is needed to enable development of therapeutics that target AMPK to control inflammation and promote host defenses against infection. This work should focus on elucidating the mechanisms by which AMPK and/or AMPK-targeting compounds modulate host defenses against infection.

Funding: We are indebted to current and past members of our laboratory for discussions and investigations that contributed to this article. We apologize to colleagues whose work and publications could not be referenced owing to space constraints. This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (MSIP) (No. 2017R1A5A2015385) and by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No. NRF-2015M3C9A2054326).

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Definition                          |
|--------------|------------------------------------|
| ADP          | Adenosine diphosphate              |
| AICAR        | 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside |
| AMP          | Adenosine monophosphate            |
| AMPK         | 5′-AMP-activated protein kinase     |
| ATF3         | Activating transcription factor 3   |
| ATP          | Adenosine triphosphate             |
| CaMKK        | Ca2+-/calmodulin-dependent protein kinase kinases |
| CCL17        | Chemokine ligand 17                |
| CVB3         | Coxsackie virus B3                  |
| Abbreviation | Description |
|--------------|-------------|
| DM           | Diabetes mellitus |
| EBOV         | Zaire Ebolavirus |
| EBV          | Epstein-Barr Virus |
| GABA         | Gamma-aminobutyric acid |
| HBV          | Hepatitis B virus |
| HCC          | Hepatocellular carcinoma |
| HCMV         | Human cytomegalovirus |
| HCV          | Hepatitis C virus |
| HIV          | Human immunodeficiency virus |
| HMGCR        | 3-hydroxy-3-methylglutaryl-CoA reductase |
| HSV-1        | Herpes Simplex Virus Type 1 |
| IFN          | Interferons |
| IL-1β        | Interleukin-1β |
| IL-37        | Interleukin-37 |
| IL-7         | Interleukin-7 |
| KSHV         | Kaposi’s sarcoma-associated herpesvirus |
| LKB1         | Liver kinase B1 |
| LMP1         | Latent membrane protein 1 |
| MAPK         | Mitogen-activated protein kinase |
| MMP-8        | Matrix metalloproteinase-8 |
| mTOR         | Mammalian target of rapamycin |
| mTORC1       | Mammalian target of rapamycin complex 1 |
| NADPH        | Nicotinamide adenine dinucleotide phosphate |
| NF-κB        | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| PPARGC1A     | Peroxisome proliferator-activated receptor-gamma, coactivator 1α |
| ROS          | Reactive oxygen species |
| RVFV         | Rift Valley Fever Virus |
| SIRT1        | Sirtuin 1 |
| SIV          | Simian immunodeficiency virus |
| SNARK        | Sucrose-non-fermenting protein kinase 1/AMP-activated protein kinase-related protein kinase |
| STING        | Stimulator of IFN genes |
| TAK1         | Transforming growth factor (TGF)-β-activated kinase 1 |
| TLR          | Toll-like receptor |
| TSC          | Tuberculous sclerosis complex |

References

1. Hardie, D.G.; Ross, F.A.; Hawley, S.A. AMPK: A nutrient and energy sensor that maintains energy homeostasis. *Nat. Rev. Mol. Cell Biol.* 2012, 13, 251–262. [CrossRef] [PubMed]
2. Gowans, G.J.; Hardie, D.G. AMPK: A cellular energy sensor primarily regulated by AMP. *Biochem. Soc. Trans.* 2014, 42, 71–75. [CrossRef] [PubMed]
3. Gowans, G.J.; Hawley, S.A.; Ross, F.A.; Hardie, D.G. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. *Cell Metab.* 2013, 18, 556–566. [CrossRef] [PubMed]
4. Shackelford, D.B.; Shaw, R.J. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. *Nat. Rev. Cancer* 2009, 9, 563–575. [CrossRef] [PubMed]
5. Faubert, B.; Boily, G.; Izreig, S.; Griss, T.; Samborska, B.; Dong, Z.; Dupuy, F.; Chambers, C.; Fuerth, B.J.; Viollet, B.; et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. *Cell Metab.* 2013, 17, 113–124. [CrossRef] [PubMed]
6. Hardie, D.G. AMP-activated protein kinase: A cellular energy sensor with a key role in metabolic disorders and in cancer. *Biochem. Soc. Trans.* 2011, 39, 1–13. [CrossRef] [PubMed]
7. Moreira, D.; Silvestre, R.; Cordeiro-da-Silva, A.; Estaquier, J.; Foretz, M.; Viollet, B. AMP-activated Protein Kinase as a Target for Pathogens: Friends or Foes? *Curr. Drug Targets* 2016, 17, 942–953. [CrossRef] [PubMed]
8. Brunton, J.; Steele, S.; Ziehr, B.; Moorman, N.; Kawula, T. Feeding uninvited guests: MTOR and AMPK set the table for intracellular pathogens. PLoS Pathog. 2013, 9, e1003552. [CrossRef] [PubMed]
9. Xie, N.; Yuan, K.; Zhou, L.; Wang, K.; Chen, H.N.; Lei, Y.; Lan, J.; Pu, Q.; Gao, W.; Zhang, L.; et al. PRKAA/AMPK restricts HBV replication through promotion of autophagic degradation. Autophagy 2016, 12, 1507–1520. [CrossRef] [PubMed]
10. Pratnner, D.; Perkins, D.J.; Vogel, S.N. AMP-activated Kinase (AMPK) Promotes Innate Immunity and Antiviral Defense through Modulation of Stimulator of Interferon Genes (STING) Signaling. J. Biol. Chem. 2017, 292, 292–304. [CrossRef] [PubMed]
11. Shin, D.M.; Yang, C.S.; Lee, J.Y.; Lee, S.J.; Choi, H.H.; Lee, H.M.; Yuk, J.M.; Harding, C.V.; Jo, E.K. Mycobacterium tuberculosis lipoprotein-induced association of TLR2 with protein kinase C zeta in lipid rafts contributes to reactive oxygen species-dependent inflammatory signalling in macrophages. Cell Microbiol. 2008, 10, 1893–1905. [CrossRef] [PubMed]
12. Yang, C.S.; Kim, J.J.; Lee, H.M.; Jin, H.S.; Lee, S.H.; Park, J.H.; Kim, J.I.; Kim, J.M.; Han, Y.M.; Lee, M.S.; et al. The AMPK-PPARalpha pathway is required for antimicrobial host defense through activation of autophagy. Autophagy 2014, 10, 785–802. [CrossRef] [PubMed]
13. Mankouri, J.; Harris, M. Viruses and the fuel sensor: The emerging link between AMPK and virus replication. Rev. Med. Virol. 2011, 21, 205–212. [CrossRef] [PubMed]
14. Rajamohan, F.; Reyes, A.R.; Frisbie, R.K.; Hoth, L.R.; Sahasrabudhe, P.; Magyar, R.; Landro, J.A.; Withka, J.M.; Silvestre, R. AMPK in Pathogens. EXS 2016, 107, 287–323. [CrossRef] [PubMed]
15. Kim, J.; Yang, G.; Kim, Y.; Kim, J.; Ha, J. AMPK activators: Mechanisms of action and physiological activities. Exp. Mol. Med. 2016, 48, e224. [CrossRef] [PubMed]
16. Wu, J.; Puppala, D.; Feng, X.; Monetti, M.; Lapworth, A.L.; Geoghegan, K.F. Chemoproteomic analysis of intertissue and interspecies isoform diversity of AMP-activated protein kinase (AMPK). J. Biol. Chem. 2013, 288, 35904–35912. [CrossRef] [PubMed]
17. Rajamohan, F.; Reyes, A.R.; Frisbie, R.K.; Hoth, L.R.; Sahasrabudhe, P.; Magyar, R.; Landro, J.A.; Withka, J.M.; Caspers, N.L.; Calabrese, M.F.; et al. Probing the enzyme kinetics, allosteric modulation and activation of alpha1- and alpha2-subunit-containing AMPK heterotrimeric complexes by pharmacological and physiological activators. Biochem. J. 2016, 473, 581–592. [CrossRef] [PubMed]
18. Woods, A.; Johnstone, S.R.; Dickerson, K.; Leiper, F.C.; Fryer, L.G.; Neumann, D.; Schlattner, U.; Wallimann, T.; Carlson, M.; Carling, D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 2003, 13, 2004–2008. [CrossRef] [PubMed]
19. Carling, D.; Aguau, K.; Woods, A.; Verhoeven, A.J.; Beri, R.K.; Brennan, C.H.; Sidell, R.; Davison, M.D.; Scott, J. Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the regulation of carbon metabolism. J. Biol. Chem. 1994, 269, 11442–11448. [PubMed]
20. Hawley, S.A.; Pan, D.A.; Mustard, K.J.; Ross, L.; Bain, J.; Edelman, A.M.; Feng, B.G.; Hardie, D.G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMPK-activated protein kinase. Cell. Metab. 2005, 2, 9–19. [CrossRef] [PubMed]
21. McBride, A.; Ghilagaber, S.; Nikolaev, A.; Hardie, D.G. The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. Cell. Metab. 2009, 9, 23–34. [CrossRef] [PubMed]
22. Viana, R.; Towler, M.C.; Pan, D.A.; Carling, D.; Viollet, B.; Hardie, D.G.; Sanz, P. A conserved sequence immediately N-terminal to the Bateman domains in AMP-activated protein kinase gamma subunits is required for the interaction with the beta subunits. J. Biol. Chem. 2007, 282, 16117–16125. [CrossRef] [PubMed]
23. Xiao, B.; Heath, R.; Saiu, P.; Leiper, F.C.; Leone, P.; Jing, C.; Walker, P.A.; Haire, L.; Eccleston, J.F.; Davis, C.T.; et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 2007, 449, 496–500. [CrossRef] [PubMed]
24. Steinberg, G.R.; Kemp, B.E. AMPK in Health and Disease. Physiol. Rev. 2009, 89, 1025–1078. [CrossRef] [PubMed]
25. Viollet, B.; Horman, S.; Leclerc, J.; Lantier, L.; Foretz, M.; Billaud, M.; Giri, S.; Andreelli, F. AMPK inhibition in health and disease. Crit. Rev. Biochem. Mol. Biol. 2010, 45, 276–295. [CrossRef] [PubMed]
26. Kim, T.S.; Shin, Y.H.; Lee, H.M.; Kim, J.K.; Choe, J.H.; Jang, J.C.; Um, S.; Jin, H.S.; Komatsu, M.; Cha, G.H.; et al. Ohmyungsamycins promote antimicrobial responses through autophagy activation via AMP-activated protein kinase pathway. Sci. Rep. 2017, 7, 3431. [CrossRef] [PubMed]
27. Mankouri, J.; Tedbury, P.R.; Greeton, S.; Hughes, M.E.; Griffin, S.D.; Dallas, M.L.; Green, K.A.; Hardie, D.G.; Peers, C.; Harris, M. Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 11549–11554. [CrossRef] [PubMed]

28. Huang, H.; Kang, R.; Wang, J.; Luo, G.; Yang, W.; Zhao, Z. Hepatitis C virus inhibits AKT-tuberosclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy. *Autophagy* **2013**, *9*, 175–195. [CrossRef] [PubMed]

29. Yu, J.W.; Sun, L.J.; Liu, W.; Zhao, Y.H.; Kang, P.; Yan, B.Z. Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1-AMPK signaling pathway. *Int. J. Infect. Dis.* **2013**, *17*, e539–e545. [CrossRef] [PubMed]

30. Tsai, W.L.; Chang, T.H.; Sun, W.C.; Chan, H.H.; Wu, C.C.; Hsu, P.I.; Cheng, J.S.; Yu, M.L. Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinase. *Oncotarget* **2017**, *8*, 91928–91937. [CrossRef] [PubMed]

31. Nakashima, K.; Takeuchi, K.; Chihara, K.; Hotta, H.; Sada, K. Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways. *Microbiol. Immunol.* **2011**, *55*, 774–782. [CrossRef] [PubMed]

32. Goto, K.; Lin, W.; Zhang, L.; Jilg, N.; Shao, R.X.; Schaefer, E.A.; Zhao, H.; Fusco, D.N.; Peng, L.F.; Kato, N.; et al. The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-beta signaling. *J. Hepatol.* **2013**, *59*, 942–948. [CrossRef] [PubMed]

33. Douglas, D.N.; Pu, C.H.; Lewis, J.T.; Bhat, R.; Anwar-Mohamed, A.; Logan, M.; Lund, G.; Addison, W.R.; Lehner, R.; Kneteman, N.M. Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus. *J. Biol. Chem.* **2016**, *291*, 1974–1990. [CrossRef] [PubMed]

34. Uematsu, T.; Fujita, T.; Nakaoka, H.J.; Hara, T.; Kobayashi, N.; Murakami, Y.; Seiki, M.; Sakamoto, T. Mint3/Apba3 depletion ameliorates severe murine influenza pneumonia and macrophage cytokine production in response to the influenza virus. *Sci. Rep.* **2016**, *6*, 37815. [CrossRef] [PubMed]

35. Yoon, J.Y.; Kwon, H.H.; Min, S.U.; Thiboutot, D.M.; Sub, D.H. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting *P. acnes*. *J. Invest. Dermatol.* **2013**, *133*, 429–440. [CrossRef] [PubMed]

36. Han, S.; Xu, J.; Guo, X.; Huang, M. Curcumin ameliorates severe influenza pneumonia via attenuating lung injury and regulating macrophage cytokines production. *Clin. Exp. Pharmacol. Physiol.* **2018**, *45*, 84–93. [CrossRef] [PubMed]

37. Zhang, H.S.; Wu, T.C.; Sang, W.W.; Ruan, Z. EGCG inhibits Tat-induced LTR transactivation: Role of Nrf2, AKT, AMPK signaling pathway. *Life Sci.* **2012**, *90*, 747–754. [CrossRef] [PubMed]

38. Wang, Z.Q.; Yu, Y.; Zhang, X.H.; Floyd, E.Z.; Cefalu, W.T. Human adenovirus 36 decreases fatty acid oxidation and increases de novo lipogenesis in primary cultured human skeletal muscle cells by promoting Cidec/FSP27 expression. *Int. J. Obes.* **2010**, *34*, 1355–1364. [CrossRef] [PubMed]

39. Moser, T.S.; Schieffer, D.; Cherry, S. AMP-activated kinase restricts Rift Valley fever virus infection by inhibiting fatty acid synthesis. *PLoS Pathog.* **2012**, *8*, e1002661. [CrossRef] [PubMed]

40. Leyton, L.; Hott, M.; Acuna, F.; Caroca, J.; Nunez, M.; Martin, C.; Zambrano, A.; Concha, M.I.; Otth, C. Nutraceutical activators of AMPK/Sirt1 axis inhibit viral production and protect neurons from neurodegenerative events triggered during HSV-1 infection. *Virus Res.* **2015**, *205*, 63–72. [CrossRef] [PubMed]

41. Xie, W.; Wang, L.; Dai, Q.; Yu, H.; He, X.; Xiong, J.; Sheng, H.; Zhang, D.; Xin, R.; Qi, Y.; et al. Activation of AMPK restricts coxsackievirus B3 replication by inhibiting lipid accumulation. *J. Mol. Cell Cardiol.* **2015**, *85*, 155–167. [CrossRef] [PubMed]

42. Lo, A.K.; Lo, K.W.; Ko, C.W.; Young, L.S.; Dawson, C.W. Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells. *J. Pathol.* **2013**, *230*, 336–346. [CrossRef] [PubMed]

43. Cheng, F.; He, M.; Jung, J.U.; Lu, C.; Gao, S.J. Suppression of Kaposi’s Sarcoma-Associated Herpesvirus Infection and Replication by S’-AMP-Activated Protein Kinase. *J. Virol.* **2016**, *90*, 6515–6525. [CrossRef] [PubMed]

44. Green, V.A.; Pelkmans, L. A Systems Survey of Progressive Host-Cell Reorganization during Rotavirus Infection. *Cell Host Microbe* **2016**, *20*, 107–120. [CrossRef] [PubMed]
45. Soto-Acosta, R.; Bautista-Carbajal, P.; Cervantes-Salazar, M.; Angel-Ambrocio, A.H.; Del Angel, R.M. DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target. PLoS Pathog. 2017, 13, e1006257. [CrossRef] [PubMed]

46. Jordan, T.X.; Randall, G. Dengue Virus Activates the AMP Kinase-mTOR Axis to Stimulate a Proviral Lipophagy. J. Virol. 2017, 91. [CrossRef] [PubMed]

47. Bagga, S.; Rawat, S.; Ajenjo, M.; Bouchard, M.J. Hepatitis B virus (HBV) X protein-mediated regulation of hepatocyte metabolic pathways affects viral replication. Virology 2016, 498, 9–22. [CrossRef] [PubMed]

48. Kondratowicz, A.S.; Hunt, C.L.; Davey, R.A.; Cherry, S.; Maury, W.J. AMP-activated protein kinase is required for the macrophocytic internalization of ebolavirus. J. Virol. 2013, 87, 746–755. [CrossRef] [PubMed]

49. Ji, W.T.; Lee, L.H.; Lin, F.L.; Wang, L.; Liu, H.J. AMP-activated protein kinase facilitates avian reovirus to induce mitogen-activated protein kinase (MAPK) p38 and MAPK kinase 3/6 signalling that is beneficial for virus replication. J. Gen. Virol. 2009, 90, 3002–3009. [CrossRef] [PubMed]

50. Chi, P.I.; Huang, W.R.; Lai, I.H.; Cheng, C.Y.; Liu, H.J. The p17 nonstructural protein of avian reovirus triggers autophagy enhancing virus replication via activation of phosphatase and tensin deleted on chromosome 10 (PTEN) and AMP-activated protein kinase (AMPK), as well as dsRNA-dependent protein kinase (PKR)/eIF2alpha signaling pathways. J. Biol. Chem. 2013, 288, 3571–3584. [CrossRef] [PubMed]

51. Martin, C.; Leyton, L.; Arancibia, Y.; Cuevas, A.; Zambrano, A.; Concha, M.I.; Otth, C. Modulation of the AMPK/Sirt1 axis during neuronal infection by herpes simplex virus type 1. J. Alzheimers Dis. 2014, 42, 301–312. [CrossRef] [PubMed]

52. Samikkannu, T.; Atluri, V.S.; Nair, M.P. HIV and Cocaine Impact Glial Metabolism: Energy Sensor AMP-activated protein kinase Role in Mitochondrial Biogenesis and Epigenetic Remodeling. Sci. Rep. 2016, 6, 31784. [CrossRef] [PubMed]

53. Terry, L.J.; Vastag, L.; Rabinowitz, J.D.; Shenk, T. Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 2012, 109, 3071–3076. [CrossRef] [PubMed]

54. Hutterer, C.; Wandinger, S.K.; Wagner, S.; Muller, R.; Stamminger, T.; Zeittrager, I.; Godl, K.; Baumgartner, R.; Strobl, S.; Marschall, M. Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK. Antivir. Res. 2013, 99, 139–148. [CrossRef] [PubMed]

55. McArdle, J.; Moorman, N.J.; Munger, J. HCMV targets the metabolic stress response through activation of AMPK whose activity is important for viral replication. PLoS Pathog. 2012, 8, e1002502. [CrossRef] [PubMed]

56. Mukhopadhyay, R.; Venkatadri, R.; Katsnelson, J.; Arav-Boger, R. Digitoxin Suppresses Human Cytomegalovirus Replication via Na⁺, K⁺/ATPase alpha1 Subunit-Dependent AMP-Activated Protein Kinase and Autophagy Activation. J. Virol. 2018, 92. [CrossRef] [PubMed]

57. Seo, J.Y.; Yaneva, R.; Hinson, E.R.; Cresswell, P. Human cytomegalovirus directly induces the antiviral protein viperin to enhance infectivity. Science 2011, 332, 1093–1097. [CrossRef] [PubMed]

58. Seo, J.Y.; Cresswell, P. Viperin regulates cellular lipid metabolism during human cytomegalovirus infection. PLoS Pathog. 2013, 9, e1003497. [CrossRef] [PubMed]

59. Li, M.; Li, J.; Zeng, R.; Yang, J.; Liu, J.; Zhang, Z.; Song, X.; Yao, Z.; Ma, C.; Li, W.; et al. Respiratory Syncytial Virus Replication Is Promoted by Autophagy-Mediated Inhibition of Apoptosis. J. Virol. 2018, 92. [CrossRef] [PubMed]

60. Lv, S.; Xu, Q.Y.; Sun, E.C.; Zhang, J.K.; Wu, D.L. Dissection and integration of the autophagy signaling network initiated by bluetongue virus infection: Crucial candidates ERK1/2, Akt and AMPK. Sci. Rep. 2016, 6, 23130. [CrossRef] [PubMed]

61. Liu, J.; Wang, H.; Gu, J.; Deng, T.; Yuan, Z.; Hu, B.; Xu, Y.; Yan, Y.; Zan, J.; Liao, M.; et al. BECN1-dependent CASP2 incomplete autophagy induction by binding to rabies virus phosphoprotein. Autophagy 2017, 13, 739–753. [CrossRef] [PubMed]

62. Subramanian, G.; Kuzmanovic, T.; Zhang, Y.; Peter, C.B.; Velepparambil, M.; Chakravarti, R.; Sen, G.C.; Chattopadhyay, S. A new mechanism of interferon’s antiviral action: Induction of autophagy, essential for paramyxovirus replication, is inhibited by the interferon stimulated gene, TDRD7. PLoS Pathog. 2018, 14, e1006877. [CrossRef] [PubMed]

63. McFadden, K.; Hafez, A.Y.; Kishston, R.; Messinger, J.E.; Nikitín, P.A.; Rathmell, J.C.; Luftig, M.A. Metabolic stress is a barrier to Epstein-Barr virus-mediated B-cell immortalization. Proc. Natl. Acad. Sci. USA 2016, 113, E782–E790. [CrossRef] [PubMed]
64. Burke, J.D.; Platanias, L.C.; Fish, E.N. Beta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3. *J. Virol.* **2014**, *88*, 3485–3495. [CrossRef] [PubMed]

65. Zhang, C.; Feng, S.; Zhang, W.; Chen, N.; Hegazy, A.M.; Chen, W.; Liu, X.; Zhao, L.; Li, J.; Lin, L.; et al. MicroRNA miR-214 inhibits Snakehead Vesiculovirus Replication by Promoting IFN-alpha Expression via Targeting Host Adenosine 5′-Monophosphate-Activated Protein Kinase. *Front. Immunol.* **2017**, *8*, 1775. [CrossRef] [PubMed]

66. Francione, L.; Smith, P.K.; Accari, S.L.; Taylor, P.E.; Bokko, P.B.; Bozzaro, S.; Beech, P.L.; Fisher, P.R. *Legionella pneumophila* multiplication is enhanced by chronic AMPK signalling in mitochondrially diseased Dictyostelium cells. *Dis. Model Mech.* **2009**, *2*, 479–489. [CrossRef] [PubMed]

67. Kajiwara, C.; Kusaka, Y.; Kimura, S.; Yamaguchi, T.; Nanjo, Y.; Ishii, Y.; Udono, H.; Standiford, T.J.; Tateda, K. Metformin Mediates Protection against *Legionella* Pneumonia through Activation of AMPK and Mitochondrial Reactive Oxygen Species. *J. Immunol.* **2018**, *200*, 623–631. [CrossRef] [PubMed]

68. Ganesan, R.; Hos, N.J.; Gutierrez, S.; Fischer, J.; Stepek, J.M.; Daglidu, E.; Kronke, M.; Robinson, N. *Salmonella Typhimurium* disrupts Sirt1/AMPK checkpoint control of mTOR to impair autophagy. *PLoS Pathog.* **2017**, *13*, e1006227. [CrossRef] [PubMed]

69. Liu, W.; Jiang, Y.; Sun, J.; Geng, S.; Pan, Z.; Prinz, R.A.; Wang, C.; Sun, J.; Jiao, X.; Xu, X. Activation of TGF-beta-activated kinase 1 (TAK1) restricts *Salmonella* Typhimurium growth by inducing AMPK activation and autophagy. *Cell Death Dis.* **2018**, *9*, 570. [CrossRef] [PubMed]

70. Tattoli, I.; Sorbara, M.T.; Philpott, D.J.; Girardin, S.E. Bacterial autophagy: The trigger, the target and the timing. *Autophagy* **2012**, *8*, 1848–1850. [CrossRef] [PubMed]

71. Neumann, D. Is TAK1 a Direct Upstream Kinase of AMPK? *Int. J. Mol. Sci.* **2018**, *19*, 2412. [CrossRef] [PubMed]

72. Liu, N.; Li, Y.; Dong, C.; Xu, X.; Wei, P.; Sun, W.; Peng, Q. Inositol-Requiring Enzyme 1-Dependent Activation of AMPK Promotes *Brucella abortus* Intracellular Growth. *J. Bacteriol.* **2016**, *198*, 986–993. [CrossRef] [PubMed]

73. Liang, Y.D.; Bai, W.J.; Li, C.G.; Xu, L.H.; Wei, H.X.; Pan, H.; He, X.H.; Ouyang, D.Y. Piperine Suppresses Pyroptosis and Interleukin-1beta Release upon ATP Triggering and Bacterial Infection. *Front. Pharmacol.* **2016**, *7*, 390. [CrossRef] [PubMed]

74. Yang, W.; Dierking, K.; Esser, D.; Tholey, A.; Leippe, M.; Rosenstiel, P.; Schulenburg, H. Overlapping and unique signatures in the proteomic and transcriptomic responses of the nematode *Caenorhabditis elegans* toward pathogenic *Bacillus thuringiensis*. *Dev. Comp. Immunol.* **2015**, *51*, 1–9. [CrossRef] [PubMed]

75. Lv, G.; Zhu, H.; Zhou, F.; Lin, Z.; Lin, G.; Li, C. AMP-activated protein kinase activation protects gastric epithelial cells from *Helicobacter pylori*-induced apoptosis. *Biochem. Biophys. Res. Commun.* **2014**, *453*, 13–18. [CrossRef] [PubMed]

76. Zhao, H.; Zhu, H.; Lin, Z.; Lin, G.; Lv, G. Compound 13, an alpha1-selective small molecule activator of AMPK, inhibits *Helicobacter pylori*-induced oxidative stresses and gastric epithelial cell apoptosis. *Biochem. Biophys. Res. Commun.* **2016**, *470*, 510–517. [CrossRef] [PubMed]

77. Patkee, W.R.; Carr, G.; Baker, E.H.; Baines, D.L.; Garnett, J.P. Metformin prevents the effects of *Pseudomonas aeruginosa* on airway epithelial tight junctions and restricts hyperglycaemia-induced bacterial growth. *J. Cell Mol. Med.* **2016**, *20*, 758–764. [CrossRef] [PubMed]

78. Kumar, A.; Giri, S.; Kumar, A. 5-Aminomidazole-4-carboxamide ribonucleoside-mediated adenosine monophosphate-activated protein kinase activation induces protective innate responses in bacterial endophthalmitis. *Cell Microbiol.* **2016**, *18*, 1815–1830. [CrossRef] [PubMed]

79. Wang, Y.; Zhang, K.; Shi, X.; Wang, C.; Wang, F.; Fan, J.; Shen, F.; Xu, J.; Bao, W.; Liu, M.; et al. Critical role of bacterial isochorismatase in the autophagic process induced by *Acinetobacter baumannii* in mammalian cells. *FASEB J.* **2016**, *30*, 3563–3577. [CrossRef] [PubMed]

80. Singhal, A.; Jie, L.; Kumar, P.; Hong, G.S.; Leow, M.K.; Paleja, B.; Tsenova, L.; Kurepina, N.; Chen, J.; Zolezzi, F.; et al. Metformin as adjunct antituberculosis therapy. *Sci. Transl. Med.* **2014**, *6*, 263ra159. [CrossRef] [PubMed]

81. Yuk, J.M.; Shin, D.M.; Lee, H.M.; Yang, C.S.; Jin, H.S.; Kim, K.K.; Lee, Z.W.; Lee, S.H.; Kim, J.M.; Jo, E.K. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. *Cell Host Microbe* **2009**, *6*, 231–243. [CrossRef] [PubMed]
82. Rekha, R.S.; Rao Muvva, S.S.; Wan, M.; Raqib, R.; Bergman, P.; Brighenti, S.; Gudmundsson, G.H.; Agerberth, B. Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages. Autophagy 2015, 11, 1688–1699. [CrossRef] [PubMed]

83. Kim, J.K.; Kim, Y.S.; Lee, H.M.; Jin, H.S.; Neupane, C.; Kim, S.; Lee, S.H.; Min, J.J.; Sasai, M.; Jeong, J.H.; et al. GABAAergic signaling linked to autophagy enhances host protection against intracellular bacterial infections. Nat. Commun. 2018, 9, 4184. [CrossRef] [PubMed]

84. Ong, C.W.; Elkington, P.T.; Brihia, S.; Ugarte-Gil, C.; Tome-Esteban, M.T.; Tezera, L.B.; Pabisiak, P.J.; Moores, R.C.; Sathyamoorthy, T.; Patel, V.; et al. Neutrophil-Derived MRP-8 Drives AMPK-Dependent Matrix Destruction in Human Pulmonary Tuberculosis. PLoS Pathog. 2015, 11, e1004917. [CrossRef] [PubMed]

85. Restrepo, B.I. Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients. Tuberculosis (Edinb) 2016, 101S, S69–S72. [CrossRef] [PubMed]

86. Ouiimet, M.; Koster, S.; Sakowski, E.; Ramkhelawon, B.; van Solingen, C.; Oldebeken, S.; Karunakaran, D.; Portal-Cellhay, C.; Sheedy, F.J.; Ray, T.D.; et al. Mycobacterium tuberculosis induces the miR-33 locus to reprogram autophagy and host lipid metabolism. Nat. Immunol. 2016, 17, 677–686. [CrossRef] [PubMed]

87. Kim, J.K.; Lee, H.M.; Park, K.S.; Shin, D.M.; Kim, T.S.; Kim, Y.S.; Suh, H.W.; Kim, S.Y.; Kim, I.S.; Kim, J.M.; et al. MIR144* inhibits antimicrobial responses against Mycobacterium tuberculosis in human monocytes and macrophages by targeting the autophagy protein DRAM2. Autophagy 2017, 13, 423–441. [CrossRef] [PubMed]

88. Dorhoi, A.; Kaufmann, S.H. Pathology and immune reactivity: Understanding multidimensionality in pulmonary tuberculosis. Semin. Immunopathol. 2016, 38, 153–166. [CrossRef] [PubMed]

89. Nieves, W.; Hung, L.Y.; Oniskey, T.K.; Boon, L.; Foretz, M.; Viollet, B.; Herbert, D.R. Myeloid-Restricted AMPKalpha1 Promotes Host Immunity and Protects against IL-12/23p40-Dependent Lung Injury during Hookworm Infection. J. Immunol. 2016, 196, 4632–4640. [CrossRef] [PubMed]

90. Moreira, D.; Rodrigues, V.; Abengozar, M.; Rivas, L.; Rial, E.; Laforge, M.; Li, X.; Foretz, M.; Viollet, B.; Estaquier, D.; et al. Leishmania infantum modulates host macrophage mitochondrial metabolism by hijacking the SIRT1-AMPK axis. PLoS Pathog. 2015, 11, e1004684. [CrossRef] [PubMed]

91. Zhu, J.; Zhang, W.; Zhang, L.; Xu, L.; Chen, X.; Zhou, S.; Xu, Z.; Xiao, M.; Bai, H.; Liu, F.; et al. IL-7 suppresses macrophage autophagy and promotes liver pathology in Schistosoma japonicum-infected mice. J. Cell. Mol. Med. 2018, 22, 3353–3363. [CrossRef] [PubMed]

92. Ruivo, M.T.G.; Vera, I.M.; Sales-Dias, J.; Meireles, P.; Gural, N.; Bhatia, S.N.; Mota, M.M.; Mancio-Silva, L. Host AMPK Is a Modulator of Plasmodium Liver Infection. Cell. Rep. 2016, 16, 2539–2545. [CrossRef] [PubMed]

93. Vilar-Pereira, G.; Carneiro, V.C.; Mata-Santos, H.; Vicentino, A.R.; Ramos, I.P.; Giarola, N.L.; Feijo, D.F.; Meyer-Fernandes, J.R.; Paula-Neto, H.A.; Medei, E.; et al. Resveratrol Reverses Functional Chagas Heart Disease in Mice. PLoS Pathog. 2016, 12, e1005947. [CrossRef] [PubMed]

94. Pandey, A.; Ding, S.L.; Qin, Q.M.; Gomez, G.; Fixon, L.; Peng, X.; Facchin da Costa, L.; Chaki, S.P.; Katepalli, M.; et al. Global Reprogramming of Host Kinase Signaling in Response to Fungal Infection. Cell Host Microbe 2017, 21, 637–649. [CrossRef] [PubMed]

95. Andris, F.; Leo, O. AMPK in lymphocyte metabolism and function. Int. Rev. Immunol. 2015, 34, 67–81. [CrossRef] [PubMed]

96. Vincent, E.E.; Coelho, P.P.; Blagih, J.; Griss, T.; Viollet, B.; Jones, R.G. Differential effects of AMPK agonists on cell growth and metabolism. Oncogene 2015, 34, 3627–3639. [CrossRef] [PubMed]

97. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C.J.; McLauchlan, H.; Klevernic, I.; Arthur, J.S.; Alessi, D.R.; Cohen, P. The selectivity of protein kinase inhibitors: A further update. Biochem. J. 2007, 408, 297–315. [CrossRef] [PubMed]

98. Myers, R.W.; Guan, H.P.; Ehrhart, J.; Petrov, A.; Prahalada, S.; Tozzo, E.; Yang, X.; Kurtz, M.M.; Trujillo, M.; Gonzalez Trotter, D.; et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science 2017, 357, 507–511. [CrossRef] [PubMed]

99. Ngoei, K.R.W.; Langendorf, C.G.; Ling, N.Y.X.; Hoque, A.; Varghese, S.; Camerino, M.A.; Walker, S.R.; Bozikis, Y.E.; Dite, T.A.; Owens, A.J.; et al. Structural Determinants for Small-Molecule Activation of Skeletal Muscle AMPK alpha2beta2gamma1 by the Glucose Importagog SC4. Cell Chem. Biol. 2018, 25, 728–737. [CrossRef] [PubMed]
100. Dite, T.A.; Langendorf, C.G.; Hoque, A.; Galic, S.; Rebello, R.J.; Ovens, A.J.; Lindqvist, L.M.; Ngoei, K.R.W.; Ling, N.X.Y.; Furic, L.; et al. AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965. J. Biol. Chem. 2018, 293, 8874–8885. [CrossRef] [PubMed]

101. Shintani, Y.; Kapoor, A.; Kaneko, M.; Smolenski, R.T.; D’Acquisto, F.; Coppen, S.R.; Harada-Shoji, N.; Lee, H.J.; Thiemermann, C.; Takashima, S.; et al. TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. Proc. Natl. Acad. Sci. USA 2013, 110, 5109–5114. [CrossRef] [PubMed]

102. Hoogendijk, A.J.; Pinhancos, S.S.; van der Poll, T.; Wieland, C.W. AMP-activated protein kinase activation by 5-aminoimidazole-4-carbox-amide-1-beta-D-ribofuranoside (AICAR) reduces lipoteichoic acid-induced lung inflammation. J. Biol. Chem. 2013, 288, 7047–7052. [CrossRef] [PubMed]

103. O’Sullivan, T.E.; Johnson, L.R.; Kang, H.H.; Sun, J.C. BNIP3- and BNIP3L-Mediated Mitophagy Promotes the Generation of Natural Killer Cell Memory. Immunity 2015, 43, 331–342. [CrossRef] [PubMed]

104. Muller-Durovic, B.; Lanna, A.; Covre, L.P.; Mills, R.S.; Henson, S.M.; Akbar, A.N. Killer Cell Lectin-like Receptor G1 Inhibits NK Cell Function through Activation of Adenosine 5′-Monophosphate-Activated Protein Kinase. J. Immunol. 2016, 197, 2891–2899. [CrossRef] [PubMed]

105. Webb, T.J.; Carey, G.B.; East, J.E.; Sun, W.; Bollino, D.R.; Kimball, A.S.; Brutkiewicz, R.R. Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses. Pathog. Dis. 2016, 74. [CrossRef] [PubMed]

106. Park, D.W.; Jiang, S.; Tadie, J.M.; Stigler, W.S.; Gao, Y.; Deshane, J.; Abraham, E.; Zmijewski, J.W. Activation of AMPK enhances neutrophil chemotaxis and bacterial killing. Mol. Med. 2013, 19, 387–398. [CrossRef] [PubMed]

107. Zhao, X.; Zmijewski, J.W.; Lorne, E.; Liu, G.; Park, Y.J.; Tsuruta, Y.; Abraham, E. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295, L497–L504. [CrossRef] [PubMed]

108. Bergheim, I.; Luyendyk, J.P.; Steele, C.; Russell, G.K.; Guo, L.; Roth, R.A.; Arteel, G.E. Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J. Pharmacol. Exp. Ther. 2006, 316, 1053–1061. [CrossRef] [PubMed]

109. Escobar, D.A.; Botero-Quintero, A.M.; Kautza, B.C.; Luciano, J.; Loughran, P.; Rosengart, M.R.; Zuckerbraun, B.S.; Gomez, H. Adenosine monophosphate-activated protein kinase activation protects against sepsis-induced organ injury and inflammation. J. Surg. Res. 2015, 194, 262–272. [CrossRef] [PubMed]

110. Hattori, Y.; Suzuki, K.; Hattori, S.; Kasai, K. Metformin inhibits cytokine-induced nuclear factor κB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006, 47, 1183–1188. [CrossRef] [PubMed]

111. Zmijewski, J.W.; Lorne, E.; Zhao, X.; Tsuruta, Y.; Sha, Y.; Liu, G.; Siegal, G.P.; Abraham, E. Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am. J. Respir. Crit. Care Med. 2008, 178, 168–179. [CrossRef] [PubMed]

112. Sag, D.; Carling, D.; Stout, R.D.; Suttles, J. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 2008, 181, 8633–8641. [CrossRef] [PubMed]

113. Xing, J.; Wang, Q.; Coughlan, K.; Viollet, B.; Moriasi, C.; Zou, M.H. Inhibition of AMP-activated protein kinase accentuates lipopolysaccharide-induced lung endothelial barrier dysfunction and lung injury in vivo. Am. J. Pathol. 2013, 182, 1021–1030. [CrossRef] [PubMed]

114. Jeong, H.W.; Hsu, K.C.; Lee, J.W.; Ham, M.; Huh, J.Y.; Shin, H.J.; Kim, W.S.; Kim, J.B. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab. 2009, 296, E955–E964. [CrossRef] [PubMed]

115. Vaez, H.; Rameshrad, M.; Najafi, M.; Barar, J.; Barzegari, A.; Garjani, A. Cardioprotective effect of metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart. Eur. J. Pharmacol. 2016, 772, 115–123. [CrossRef] [PubMed]

116. Kim, J.; Kwak, H.J.; Cha, J.Y.; Jeong, Y.S.; Rhee, S.D.; Kim, K.R.; Cheon, H.G. Metformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction. J. Biol. Chem. 2014, 289, 23246–23255. [CrossRef] [PubMed]

117. Mulchandani, N.; Yang, W.L.; Khan, M.M.; Zhang, F.; Marambaud, P.; Nicastro, J.; Coppa, G.F.; Wang, P. Stimulation of Brain AMP-Activated Protein Kinase Attenuates Inflammation and Acute Lung Injury in Sepsis. Mol. Med. 2015, 21, 637–644. [CrossRef] [PubMed]
118. Liu, Z.; Bone, N.; Jiang, S.; Park, D.W.; Tadie, J.M.; Deshane, J.; Rodriguez, C.A.; Pittet, J.F.; Abraham, E.; Zmijewski, J.W. AMP-Activated Protein Kinase and Glycogen Synthase Kinase 3beta Modulate the Severity of Sepsis-Induced Lung Injury. *Mol. Med.* 2016, 21, 937–950. [CrossRef] [PubMed]

119. Chen, J.; Lai, J.; Yang, L.; Ruan, G.; Chaugai, S.; Ning, Q.; Chen, C.; Wang, D.W. Trimetazidine prevents macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin 1. *Br. J. Pharmcol.* 2016, 173, 545–561. [CrossRef] [PubMed]

120. Liu, X.; Wang, N.; Fan, S.; Zheng, X.; Yang, Y.; Zhu, Y.; Lu, Y.; Chen, Q.; Zhou, H.; Zheng, J. The citrus flavonoid naringenin confers protection in a murine endotoxaemia model through AMPK-ATF3-dependent negative regulation of the TLR4 signalling pathway. *Sci. Rep.* 2016, 6, 39735. [CrossRef] [PubMed]

121. Zhan, W.; Kang, Y.; Chen, N.; Mao, C.; Kang, Y.; Shang, J. Halofuginone ameliorates inflammation in severe acute hepatitis B virus (HBV)-infected SD rats through AMPK activation. *Drug Des. Dev. Ther.* 2017, 11, 2947–2955. [CrossRef] [PubMed]

122. Bae, H.B.; Zmijewski, J.W.; Deshane, J.S.; Tadie, J.M.; Chaplin, D.D.; Takashima, S.; Abraham, E. AMP-activated protein kinase enhances the phagocytic ability of macrophages and neutrophils. *FASEB J.* 2011, 25, 4358–4368. [CrossRef] [PubMed]

123. Li, L.; Xu, S.; Guo, T.; Gong, S.; Zhang, C. Effect of dapagliflozin on intestinal flora in MafA-deficient mice. *Curr. Pharm. Des.* 2018. [CrossRef] [PubMed]

124. Rousset, C.I.; Leiper, F.C.; Kichev, A.; Gressens, P.; Carling, D.; Hagberg, H.; Thornton, C. A dual role for AMP-activated protein kinase (AMPK) during neonatal hypoxic-ischaemic brain injury in mice. *J. Neurochem.* 2015, 133, 242–252. [CrossRef] [PubMed]

125. Li, C.G.; Yan, L.; Jing, Y.Y.; Xu, L.H.; Liang, Y.D.; Wei, H.X.; Hu, B.; Pan, H.; Zha, Q.B.; Ouyang, D.Y.; et al. Berberine augments ATP-induced inflammasome activation in macrophages by enhancing AMPK signaling. *Oncotarget* 2017, 8, 95–109. [CrossRef] [PubMed]

126. Zha, Q.B.; Wei, H.X.; Li, C.G.; Liang, Y.D.; Xu, L.H.; Bai, W.J.; Pan, H.; He, X.H.; Ouyang, D.Y. ATP-Induced Inflammasome Activation and Pyroptosis Is Regulated by AMPK-Activated Protein Kinase in Macrophages. *Front. Immunol.* 2016, 7, 597. [CrossRef] [PubMed]

127. Wen, H.; Gris, D.; Lei, Y.; Jha, S.; Zhang, L.; Huang, M.T.; Brickey, W.J.; Ting, J.P. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. *Nat. Immunol.* 2011, 12, 408–415. [CrossRef] [PubMed]

128. Bullon, P.; Alcocer-Gomez, E.; Carrion, A.M.; Marin-Aguilar, F.; Garrido-Maraver, J.; Roman-Malo, L.; Ruiz-Cabello, J.; Cunic, O.; Ryffel, B.; Apetoh, L.; et al. AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome. *Antioxid. Redox. Signal.* 2016, 24, 157–170. [CrossRef] [PubMed]

129. Wang, Y.; Viollet, B.; Terkeltaub, R.; Liu-Bryan, R. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. *Ann. Rheum. Dis.* 2016, 75, 286–294. [CrossRef] [PubMed]

130. Blagih, J.; Coulombe, F.; Vincent, E.E.; Dupuy, F.; Galicia-Vazquez, G.; Yurchenko, E.; Raissi, T.C.; van der Windt, G.J.; Viollet, B.; Pearce, E.L.; et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. *Immunity* 2015, 42, 41–54. [CrossRef] [PubMed]

131. Iseda, S.; Takahashi, N.; Poplimont, H.; Nomura, T.; Seki, S.; Nakane, T.; Nakamura, M.; Shi, S.; Ishii, H.; Furukawa, S.; et al. Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization. *J. Virol.* 2016, 90, 6276–6290. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).